Osteoporosis News

Researchers have used a 3-D printer to create a bone-like material and structure that can be used in orthopedic procedures and may clear the way for custom-made replacement tissue, according to a Washington State University news release.

The use of angiotensin-coverting enzyme inhibitors can marginally increase bone loss in older men, according to this study from researchers in Hong Kong.

Overweight and obese premenopausal women who increased dairy food and protein intake during weight loss regimens developed improved markers for bone formation and decreased markers for bone degradation, according to a study set for publication in the Journal of Clinical Endocrinology & Metabolism.

Monthly administration of minodronate at doses of 30 mg or 50 mg has been found by Japanese researchers to have similar impact on bone mineral density and bone turnover markers to a daily 1 mg dose, according to this study.

A recently issued audit report by the International Osteoporosis Foundation indicates that osteoporosis is a growing problem in the Middle East and areas of Africa, and calls for more research to aid in the development of comprehensive health care policies in these regions.

Researchers at the Institut de recherches cliniques de Montreal have identified a gene that modulates bone mass and could become a risk factor for the development of osteoporosis.

GOTHENBURG, Sweden — Bedrest leads to slightly more nonunions than two other conservative approaches for treating osteoporotic thoracolumbar vertebral compression fractures, according to a study recently presented by Japanese investigators.

COPENHAGEN, Denmark — A comparison of balloon kyphoplasty with vertebroplasty has shown that both methods are safe and effective for the treatment of pain and disability associated with osteoporotic vertebral compression fractures, according to a recent presentation.

Percutaneous vertebroplasty remains a viable option for patients with osteoporotic compression fractures with intravertebral clefts, but may not be a superior treatment because of its delayed treatment benefits, according to a recent presentation.

The FDA's Reproductive Health Drugs Advisory Committee and the Drug Safety and Risk Management Advisory Committee today voted 17-6 to add clarifications to bisphosphonate labeling regarding duration of use and timing of evaluation.